Dallas, TX - A team of biochemists has elucidated the 3-dimensional structure of a low-density lipoprotein (LDL) receptor during 1 stage of the process in which it releases LDL. The discovery may aid ...

Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it ...

As clinicians, we know that lowering low-density lipoprotein cholesterol (LDL-C) with statins alone or in combination with nonstatin therapies such as a proprotein convertase subtilisin/kexin type 9 ...

Large primary care study from Naples finds that lower LDL cholesterol is linked with a higher chance of developing type 2 diabetes Statin treatment raises diabetes risk at every LDL level, but the ...